NCT06164314 Perioperative Dexmedetomidine on Postoperative Delirium in Patients With Brain Tumors
| NCT ID | NCT06164314 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tiantan Hospital |
| Condition | Postoperative Delirium |
| Study Type | INTERVENTIONAL |
| Enrollment | 366 participants |
| Start Date | 2024-01-25 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 366 participants in total. It began in 2024-01-25 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Neurosurgery is a risk factor for delirium. Dexmedetomidine might reduce delirium by reducing neuroinflammation, improving postoperative analgesia and sleep quality. The the primary hypothesis is that perioperative administration of dexmedetomidine can reduce the incidence of postoperative delirium
Eligibility Criteria
Inclusion Criteria: * Patients with temporal glioma scheduled for a elective craniotomy * Age ≥18 years * Obtain written informed consent. Exclusion Criteria: * Patients with severe preoperative cognitive impairment * History of traumatic brain injury or previous neurosurgery * History of psychotropic medications * Allergy to dexmedetomidine * Pregnant or lactating women * History of obstructive sleep apnoea syndrome * Severe bradycardia(heart rate \<40 beats/min), sick sinus syndrome or second-to-third degree atrioventricular block * Severe hepatic dysfunction * Severe renal dysfunction
Contact & Investigator
Yuming Peng
PRINCIPAL INVESTIGATOR
Beijing Tiantan Hospital
Frequently Asked Questions
Who can join the NCT06164314 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Postoperative Delirium. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06164314 currently recruiting?
Yes, NCT06164314 is actively recruiting participants. Contact the research team at florapym766@163.com for enrollment information.
Where is the NCT06164314 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06164314 clinical trial?
NCT06164314 is sponsored by Beijing Tiantan Hospital. The principal investigator is Yuming Peng at Beijing Tiantan Hospital. The trial plans to enroll 366 participants.